PMID- 19109802
OWN - NLM
STAT- MEDLINE
DCOM- 20090323
LR  - 20090129
IS  - 1099-1557 (Electronic)
IS  - 1053-8569 (Linking)
VI  - 18
IP  - 2
DP  - 2009 Feb
TI  - Risk of acute myocardial infarction in patients treated with thiazolidinediones 
      or other antidiabetic medications.
PG  - 166-74
LID - 10.1002/pds.1700 [doi]
AB  - PURPOSE: Controversy surrounds the question whether thiazolidinediones (TZDs) 
      increase the risk of acute myocardial infarction (AMI). This study examined risk 
      of AMI in patients with type 2 diabetes mellitus (T2DM) who were taking TZDs or 
      other antidiabetic medications. METHODS: Using a nested case-control design, a 
      cohort of patients aged 18-84 years with T2DM and use of an oral antidiabetic 
      medication or exenatide between January 2002 and June 2006 was identified. Cases 
      of AMI were matched with up to four controls based on age, gender, health plan, 
      geography, and diabetes therapy regimen. Over the 1-year pre-index period, TZD 
      exposure was compared with no TZD exposure, after adjustment for potential 
      confounders. RESULTS: Overall, 1681 cases were identified and matched with 6653 
      controls. Compared with no TZD exposure, an increased risk of AMI was not 
      observed among TZD exposed patients (adjusted OR 1.01; 95%CI, 0.85-1.20; adjusted 
      p = 0.98). When exposure proximity to the event was examined, the risk of AMI was 
      significantly increased with recent rosiglitazone exposure between 1 and 60 days 
      prior to the case date (adjusted OR 1.69; 95%CI, 1.18-2.44; adjusted p = 0.045) 
      and was not significantly increased with current or remote rosiglitazone exposure 
      or current, recent, or remote pioglitazone exposure. CONCLUSION: TZD exposure did 
      not increase the risk of AMI when exposure proximity was not considered. However, 
      when evaluating exposure proximity to the event, the risk of AMI was increased 
      with recent rosiglitazone exposure between 1 and 60 days prior to the case date.
FAU - Stockl, Karen M
AU  - Stockl KM
AD  - Clinical Analytics, Clinical Services Department, Prescription Solutions, 2300 
      Main Street, Mail Stop CA134-0404, Irvine, CA 92614, USA. 
      Karen.stockl@prescriptionsolutions.com
FAU - Le, Lisa
AU  - Le L
FAU - Zhang, Shaoang
AU  - Zhang S
FAU - Harada, Ann S M
AU  - Harada AS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Pharmacoepidemiol Drug Saf
JT  - Pharmacoepidemiology and drug safety
JID - 9208369
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology
MH  - Drug Prescriptions/statistics & numerical data
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*adverse effects/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*chemically induced/epidemiology
MH  - Regression Analysis
MH  - Risk
MH  - Thiazolidinediones/administration & dosage/*adverse effects/therapeutic use
MH  - United States/epidemiology
MH  - Young Adult
EDAT- 2008/12/26 09:00
MHDA- 2009/03/24 09:00
CRDT- 2008/12/26 09:00
PHST- 2008/12/26 09:00 [entrez]
PHST- 2008/12/26 09:00 [pubmed]
PHST- 2009/03/24 09:00 [medline]
AID - 10.1002/pds.1700 [doi]
PST - ppublish
SO  - Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.